<DOC>
	<DOCNO>NCT02685189</DOCNO>
	<brief_summary>The purpose protocol provide mechanism collect Long Term Clinical Data baby participate primary Study 64,185-06-2 ( W ) ( WS ) ( ISNHP ) `` An Open-Label Study Of The Safety And Clinical Pharmacology Of Stanate® In Infants At-Risk For Exchange Transfusion '' .</brief_summary>
	<brief_title>Long-Term Clinical Follow-Up Children Enrolled Stannsoporfin Clinical Trial Protocol No . 64,185-06-2 ( W )</brief_title>
	<detailed_description>The purpose protocol provide mechanism collect Clinical Data baby participate primary Study 64,185-06-2 ( W ) ( WS ) ( ISNHP ) `` An Open-Label Study Of The Safety And Clinical Pharmacology Of Stanate® In Infants At-Risk For Exchange Transfusion '' . Data long-term impact Stannsoporfin physical , neurological , neurodevelopmental , biochemical , metabolic hematopoietic profile child collect 9 18 month , 3 , 6 9 year Stannsoporfin administration</detailed_description>
	<mesh_term>Hyperbilirubinemia</mesh_term>
	<mesh_term>Tin mesoporphyrin</mesh_term>
	<criteria>All child enrol receive Stanate® Injection/Placebo Study Protocol 64,185062 ( W ) ( WS ) ( ISNHP ) eligible followup .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>60 Days</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>